Application of T-LAK cell-originated protein kinase (TOPK) serving as cisplatin resistance therapy target for cervical cancer

• Main Authors: MA HANLIN, QI GONGHUA, KONG BEIHUA, YUAN CUNZHONG
• Format: Patent
• Language: Chinese; English
• Published: 09.06.2020
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

The invention belongs to the field of anti-cervical cancer drugs, and particularly relates to application of T-LAK cell-originated protein kinase (TOPK) serving as a cisplatin resistance therapy target for cervical cancer. In the prior art, a relationship between the TOPK and cervical cancer prolife...